About GLPG
GLPG is a publicly listed company based in Mechelen (Belgium) founded in 1999. Small molecule drugs for immunology and oncology are developed. GLPG has raised $26.1 million across 21 funding rounds from investors including Gilead, Apax Partners and Crucell. The company has 704 employees. GLPG has completed 3 acquisitions, including Abound Bio, CellPoint and Inpharmatica. Its website glpg.com draws about 29 thousand monthly visits. GLPG offers products and services including Cell Therapy Platform and Small Molecules. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is Galapagos NV.
Company details
Founded in 1999 and headquartered in Mechelen, Belgium, small molecule drugs and antibody programs are discovered and developed by the company. Focus is placed on immunology, oncology, cystic fibrosis, inflammation, and other indications within the biotechnology sector. Operations involve advancing therapeutic candidates through research and clinical stages for various diseases.
- Annual Revenue$286.37 M (USD)14.99as on Dec 31, 2024
- Net Profit$76.96 M (USD)-65.01as on Dec 31, 2024
- EBITDA-$190.76 M (USD)-99.8as on Dec 31, 2024
- Total Equity Funding$26.1M (USD)
in 21 rounds
- Latest Funding Round$410.58M (USD), Post-IPO
Nov 2019
- InvestorsGilead
& 10 more
- Employee Count704
- Investments & AcquisitionsAbound Bio
& 2 more
Products & Services of GLPG
GLPG offers a comprehensive portfolio of products and services, including Cell Therapy Platform and Small Molecules.
Develops scalable cell therapies for oncology and hematological needs.
Assets targeting auto-immune diseases through clinical trials.
Funding Insights of GLPG
GLPG has successfully raised a total of $26.1M across 21 strategic funding rounds. The most recent funding activity was a Post-IPO round of $410.58 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.1M
- Total Rounds 21
- Last Round Post-IPO — $410.58M
- Investors Count 11
Latest 10 of 21 funding rounds of GLPG with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $410.58M | Post-IPO | – | – | |
| Jun 2019 | $4.85M | Post-IPO | – | – | – |
| Jan 2018 | $32,429 | Grant | – | – | |
| Jan 2016 | $277,336 | Grant | – | – | |
| Oct 2015 | $1.34M | Post-IPO | – | – | – |
| Jun 2015 | $5M | Post-IPO | – | – | – |
| Feb 2015 | $1.81M | Grant | – | – | |
| Jan 2015 | $2.89M | Grant | – | – | |
| Feb 2014 | $3.14M | Grant | – | – | |
| Jan 2014 | $3.87M | Grant | – | – |
11 investors in total: 11 institutional.
Investors in GLPG
GLPG has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Apax Partners and Crucell.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Equity investments are focused on tech, services, and consumer sectors. | 1981 | apax.com | Hong Kong, China | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | gilead.com | Foster City, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
A platform for online casino gaming in Belgium is provided. | iwt.be | Belgium | ||
International trade fairs and events are organized globally. | 1947 | messe.de | Hannover, Germany | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Crucell researches and develops products and markets vaccines, proteins and antibodies for the treatment of infectious diseases | 1993 | crucell.com | Leiden, Netherlands |
Investor details for GLPG
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GLPG
35 people are tracked at GLPG (11 in leadership, 6 in board & advisors, 18 in team); the tracked headcount is 704.
| Name | Role | Group |
|---|---|---|
Karin Vaneynde | Associate Director, International Payroll Lead | Leadership |
Thomas Bedert | Senior Legal Counsel, Senior Director, Research & Development | Leadership |
Paul Stoffels | CEO & Chair | Leadership |
Patrik Ringblom | Head, Strategy & US Lead | Leadership |
Dominique de Picker | Sr. Executive Assistant To The CEO And Chairman Of The Board, Associate Director | Leadership |
Willemijn Kremer | Corporate Development Lead Cell Therapy & Chief Of Staff - Vice President (vp) | Leadership |
Ramzi Amri | Vice President, Head Of Development Strategy And Execution | Leadership |
Juliette Alsberge | Talent Acquisition Partner | Leadership |
David Schoonens | Sr. Director, Head Of Global Payroll, HR Services, Mobility, HRIS & Analytics At Galapagos | Leadership |
Mitja Andlovec | Head Of Information Security & Risk Management (isrm) / CISO (kvalito Group) | Leadership |
Richella Soetens | Senior Legal Counsel, Director, Research & Development At Galapagos | Leadership |
Elisabeth Svanberg | Non-Executive Independent Director | Board & advisors |
Jérôme Contamine | Non-Executive Independent Director | Board & advisors |
Susanne Schaffert | Non-Executive Independent Director | Board & advisors |
Andrew Dickinson | Director | Board & advisors |
Simon Sturge | Non-Executive Independent Director | Board & advisors |
Oleg Nodelman | Non-Executive Non-Independent Director | Board & advisors |
Valeria Cnossen | General Counsel | Team |
David Chaker | Strategy & Transformation Consultant | Team |
Annelies Missotten | CHRO | Team |
15 more people are available in the full profile.
Complete people profiles for GLPG
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GLPG
GLPG is a publicly listed company on the EURONEXT with ticker symbol GLPG in Netherlands, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 May 2015
- Listed onNASDAQ: GLPG
- Listed entityGalapagos NV
- Exchange sectorHealth technology
- ISINBE0003818359
- Share price24.40 EUR (-0.89% on the day) · 2026-05-07
- Market capitalisation1,622,385,964.00 EUR
- Price to earnings5.0
- EPS (diluted, trailing year)4.87 EUR
- Volume (last session)17,094
- Analyst consensusNeutral
Financials of GLPG
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.11B EUR | 320.9M EUR | 521.5M EUR |
| 2024 | 275.6M EUR | 74.1M EUR | -179.3M EUR |
| 2023 | 239.7M EUR | 211.7M EUR | -91.9M EUR |
| 2022 | 241.2M EUR | -218.0M EUR | -101.6M EUR |
| 2021 | 484.9M EUR | -125.4M EUR | -184.7M EUR |
Detailed financial statements for GLPG
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GLPG
GLPG has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Abound Bio, CellPoint and Inpharmatica.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of discover, development, and manufacturing services for cancer and infectious disease | aboundbio.com | Pittsburgh, United States | 2019 | Jun 2022 | $14M | |
CAR-T cell therapeutics are provided for hematological malignancies. | cellpoint.bio | Leiden, Netherlands | 2018 | Jun 2022 | $251M | |
Developer of predictive informatics based platform for drug discovery | inpharmatica.co.uk | London, United Kingdom | 1998 | Dec 2006 | •••• |
Complete acquisition details for GLPG
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of GLPG
7 dated milestones of GLPG across 23 years, from founding to its latest funding, stage changes and deals.
- Founded GLPG is founded.
- Funding First funding round.
- Acquisition Acquires Inpharmatica.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $410.6M.
- Acquisition Acquires Abound Bio.
- Acquisition Acquires CellPoint.
Web traffic of GLPG
The website of GLPG (glpg.com) receives about 29.3K visits a month.
- Monthly visits29.3K
▲ 5% vs previous month
Websites whose visitors overlap most with GLPG. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| attagene.com | 100% | View details | |||
| imgenex.com | 100% | View details | |||
arborea.ulaval.ca | arborea.ulaval.ca | 100% | – | ||
aclame.ulb.ac.be | aclame.ulb.ac.be | 100% | – | ||
| cfgbiotech.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for GLPG
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glpg
Complete news archive for GLPG
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GLPG
GLPG was founded in 1999.
GLPG is headquartered in Mechelen, Belgium. It is registered at Mechelen, Antwerp, Belgium.
GLPG is a funded company, having raised a total of $26.1M across 21 funding rounds to date. The company's 1st funding round was a Grant of $3.87M, raised on Jun 1999.
GLPG has 704 employees.
Annual revenue of GLPG is $286.37M as on Dec 31, 2024.
Founded in 1999 and headquartered in Mechelen, Belgium, small molecule drugs and antibody programs are discovered and developed by the company. Focus is placed on immunology, oncology, cystic fibrosis, inflammation, and other indications within the biotechnology sector. Operations involve advancing therapeutic candidates through research and clinical stages for various diseases.
GLPG offers Cell Therapy Platform and Small Molecules.
Yes, GLPG is publicly traded on EURONEXT under the ticker symbol GLPG.
GLPG has made 3 acquisitions, including Abound Bio, CellPoint, and Inpharmatica.
GLPG has 11 investors. Key investors include Gilead, Apax Partners, Crucell, Gimv, and European Union.
GLPG operates through Galapagos Nv.